Daré Bioscience (DARE) Competitors $2.88 -0.01 (-0.35%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. JAGX, PLRX, VTYX, BDTX, ARTV, CRBU, IFRX, ATOS, ORMP, and IZTCShould you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Jaguar Health (JAGX), Pliant Therapeutics (PLRX), Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX), Artiva Biotherapeutics (ARTV), Caribou Biosciences (CRBU), InflaRx (IFRX), Atossa Therapeutics (ATOS), Oramed Pharmaceuticals (ORMP), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry. Daré Bioscience vs. Jaguar Health Pliant Therapeutics Ventyx Biosciences Black Diamond Therapeutics Artiva Biotherapeutics Caribou Biosciences InflaRx Atossa Therapeutics Oramed Pharmaceuticals Invizyne Technologies Jaguar Health (NASDAQ:JAGX) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Do institutionals and insiders hold more shares of JAGX or DARE? 12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are held by institutional investors. 0.4% of Jaguar Health shares are held by insiders. Comparatively, 4.0% of Daré Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer JAGX or DARE? In the previous week, Jaguar Health had 4 more articles in the media than Daré Bioscience. MarketBeat recorded 9 mentions for Jaguar Health and 5 mentions for Daré Bioscience. Jaguar Health's average media sentiment score of 0.46 beat Daré Bioscience's score of 0.22 indicating that Jaguar Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jaguar Health 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daré Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, JAGX or DARE? Daré Bioscience has lower revenue, but higher earnings than Jaguar Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJaguar Health$10.48M7.83-$41.30MN/AN/ADaré Bioscience$1.88M13.32-$30.16M-$0.59-4.88 Does the MarketBeat Community prefer JAGX or DARE? Jaguar Health received 1478 more outperform votes than Daré Bioscience when rated by MarketBeat users. Likewise, 88.65% of users gave Jaguar Health an outperform vote while only 73.31% of users gave Daré Bioscience an outperform vote. CompanyUnderperformOutperformJaguar HealthOutperform Votes183588.65% Underperform Votes23511.35%Daré BioscienceOutperform Votes35773.31% Underperform Votes13026.69% Is JAGX or DARE more profitable? Daré Bioscience has a net margin of -191.65% compared to Jaguar Health's net margin of -360.13%. Daré Bioscience's return on equity of 0.00% beat Jaguar Health's return on equity.Company Net Margins Return on Equity Return on Assets Jaguar Health-360.13% -326.62% -67.02% Daré Bioscience -191.65%N/A -18.98% Which has more risk & volatility, JAGX or DARE? Jaguar Health has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Do analysts prefer JAGX or DARE? Daré Bioscience has a consensus price target of $24.00, suggesting a potential upside of 733.33%. Given Daré Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Daré Bioscience is more favorable than Jaguar Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Daré Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryDaré Bioscience beats Jaguar Health on 10 of the 16 factors compared between the two stocks. Remove Ads Get Daré Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDaré BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.06M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-4.887.1723.3318.67Price / Sales13.32220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book-4.726.396.894.23Net Income-$30.16M$142.12M$3.20B$247.15M7 Day Performance-0.35%-5.06%-2.98%-2.17%1 Month Performance-8.28%-7.49%1.63%-5.68%1 Year Performance-51.04%-10.91%9.44%-0.74% Daré Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDaré Bioscience1.6071 of 5 stars$2.88-0.3%$24.00+733.3%-51.0%$25.06M$1.88M-4.8830Upcoming EarningsShort Interest ↑News CoverageJAGXJaguar Health0.5747 of 5 stars$6.04+4.6%N/A-96.3%$99.07M$10.48M0.0050Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumePLRXPliant Therapeutics4.2852 of 5 stars$1.59+2.6%$13.31+737.3%-90.1%$97.37M$1.58M-0.4890Short Interest ↑VTYXVentyx Biosciences2.1922 of 5 stars$1.36+3.0%$10.00+635.3%-78.0%$96.74MN/A-0.5830Positive NewsBDTXBlack Diamond Therapeutics3.3404 of 5 stars$1.68-5.6%$14.60+769.0%-68.2%$95.19MN/A-1.2690High Trading VolumeARTVArtiva BiotherapeuticsN/A$3.91-8.4%$21.00+437.1%N/A$94.97M$2.60M0.0081Analyst ForecastAnalyst RevisionNews CoverageCRBUCaribou Biosciences3.3784 of 5 stars$1.02-1.9%$10.33+913.1%-81.7%$94.87M$9.99M-0.62100Short Interest ↓IFRXInflaRx2.3924 of 5 stars$1.41+10.2%$8.00+467.4%-25.3%$94.66M$165,789.00-1.3160Analyst ForecastHigh Trading VolumeATOSAtossa Therapeutics1.8827 of 5 stars$0.75-0.5%$7.00+833.3%-61.3%$94.35MN/A-3.418Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageORMPOramed Pharmaceuticals1.655 of 5 stars$2.34+0.4%N/A-24.3%$94.33M$1.34M21.2710Earnings ReportUpcoming EarningsIZTCInvizyne TechnologiesN/A$14.81-1.9%N/AN/A$92.59MN/A0.00N/ANews CoverageGap Down Remove Ads Related Companies and Tools Related Companies Jaguar Health Alternatives Pliant Therapeutics Alternatives Ventyx Biosciences Alternatives Black Diamond Therapeutics Alternatives Artiva Biotherapeutics Alternatives Caribou Biosciences Alternatives InflaRx Alternatives Atossa Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Invizyne Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DARE Stock Free DARE Stock Alerts